文献速递免疫规划

工程化降低构象可塑性的V1V2免疫原诱导交叉反应性HIV-1特异性抗体应答

Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity.
PubMed 文献 · Vaccine · 2020-03-17

RV144试验中抗HIV-1 V1V2环抗体是降低感染风险的唯一相关因素。本研究在小鼠模型中比较野生型与K155M V1V2免疫原的免疫原性,发现K155M变异体(尤其在gp120背景下)诱导更强、更持久且交叉反应性的抗体应答,限制β链V1V2构象可能与诱导保护性疫苗所需的交叉反应抗体相关。

要点

  • RV144试验中V1V2环抗体是降低HIV-1感染风险的唯一相关因素。
  • K155M变异体增强交叉反应抗体对β链构象的识别。
  • K155M免疫原(尤其gp120背景)诱导更强、更持久交叉反应抗体。

核心结论

  • 限制K155M免疫原中β链V1V2构象可能与诱导保护性HIV-1疫苗所需的交叉反应抗体应答相关。

研究设计与样本

  • 在两种小鼠模型中比较野生型与K155M V1V2免疫原的免疫原性。
  • 第二种模型比较gp70 V1V2、gD V1V2和gp120背景下K155M对免疫原性的影响,考察支架、表位聚焦和免疫方案的作用。

主要发现

  • 在一种模型中,gp70 V1V2 K155M免疫诱导对一组异源gp120和gp140抗原交叉反应的抗体应答,而野生型未诱导。
  • K155M变异体(尤其在gp120免疫原背景下)比野生型免疫原诱导更稳健、更持久和交叉反应性的抗体应答。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibodies against the HIV-1 V1V2 loops were the only correlate of reduced infection risk in the RV144 vaccine trial, highlighting the V1V2 loops as promising targets for vaccine design. The V1V2 loops are structurally plastic, exhibiting either an α-helix-coil or β-strand conformation. V1V2-specific antibodies may thus recognize distinct conformations, and an antibody's conformational specificity can be an important determinant of breadth and function. Restricting V1V2 conformational plasticity in an immunogen may thus provide control over the conformational specificity and quality of a vaccine-elicited antibody response. Previously, we identified a V1V2 sequence variant (K155M) that results in enhanced recognition by cross-reactive antibodies recognizing the β-strand conformation. Here, we relate V1V2 antigenicity to immunogenicity by comparing the immunogenicity profiles of wildtype and K155M immunogens in two mouse models. In one model, immunization with gp70 V1V2 K155M but not wildtype elicited antibody responses that were cross-reactive to a panel of heterologous gp120 and gp140 antigens. In a second model, we compared the effect of K155M on immunogenicity in the context of gp70 V1V2, gD V1V2 and gp120, examining the effects of scaffold, epitope-focusing and immunization regimen. K155M variants, especially in the context of a gp120 immunogen, resulted in more robust, durable and cross-reactive antibody responses than wildtype immunogens. Restriction of the β-stranded V1V2 conformation in K155M immunogens may thus be associated with the induction of cross-reactive antibody responses thought to be required of a protective HIV-1 vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lai JI, Eszterhas SK, Brooks SA, et al. Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity. Vaccine. 2020. PMID: 32192810. doi:10.1016/j.vaccine.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。